Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biopharmx Corp (BPMX)

Biopharmx Corp (BPMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the appointment of Steven M. Bosacki, a 20...

BPMX : 0.32 (-1.58%)
Thinking about buying stock in Allergan, Biopharmx, Beyond Meat, Immunic, or Riot Blockchain?

InvestorsObserver issues critical PriceWatch Alerts for AGN, BPMX, BYND, IMUX, and RIOT.

BPMX : 0.32 (-1.58%)
AGN : 159.11 (-0.09%)
RIOT : 1.91 (+1.60%)
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical...

BPMX : 0.32 (-1.58%)
BioPharmX Announces Reverse Stock Split

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors...

BPMX : 0.32 (-1.58%)
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...

ZUMZ : 23.70 (-0.75%)
CATB : 6.60 (+4.10%)
GNL : 19.58 (-0.91%)
BPMX : 0.32 (-1.58%)
TTMI : 10.37 (-1.61%)
PLX : 0.25 (unch)
BioPharmX Announces $3.9 Million Offering

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase...

BPMX : 0.32 (-1.58%)
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced presentations at multiple upcoming investor...

BPMX : 0.32 (-1.58%)
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter and year ended...

BPMX : 0.32 (-1.58%)
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has completed enrollment of its Phase...

BPMX : 0.32 (-1.58%)
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on February 25, 2019 from...

BPMX : 0.32 (-1.58%)
BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced the appointment of veteran pharmaceutical...

BPMX : 0.32 (-1.58%)
Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Match Group, Inc. (NASDAQ:MTCH),...

AR : 3.60 (-4.00%)
BPMX : 0.32 (-1.58%)
MTCH : 83.17 (+0.30%)
GRC : 30.23 (-0.56%)
LPTX : 1.52 (-1.30%)
BYD : 23.45 (+0.64%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -1.06 , WELL -0.87 , SBAC -0.79 , CCI -0.35 , SO -0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar